3D printing solutions provider Easy 3D Made (Chinese:易制科技) announced its completion of B-round financing, led by Hengqin Heshijia (Chinese: 横琴合世家), Horus Capital (Chinese: 华耀资本) and New World Development (Chinese: 新世界集团). The company specializes in developing advanced 3D printing products, and key features include selective laser sintering, fuse deposition molding, thin laminate manufacturing and projection light curing, providing high-quality 3D printing solutions for various industries.
InterBio (Chinese: 英柏生物) is a developer of bioanalytical instrumentation software and hardware, designed for optical surface plasmon resonance technology. It announced that it successfully completed its pre-A round of financing without specifying the amount raised. This investment was led by Jintan Capital (Chinese: 金坛资本) The funds raised will be primarily used for the R&D of products, marketing and hiring of InterBio 's technical team.
Fine Vision (Chinese: 仙微视觉) announced that it had raised nearly CNY 50 million in Angel Round, which was led by DingXin Capital (Chinese: 鼎心资本) and followed by Nanjing Innovation Capital Group (Chinese: 南京创投集团). Potential Capital (Chinese: 取势资本) acted as the exclusive financial adviser. Proceeds raised in this fund will be used in the R&D and industrialization of Small Incision Lenticule Extraction (SMILE) surgery equipment. Founded in 2022, Fine Vision is an ophthalmic diseases solution provider, focusing on the development and application of SMILE on ophthalmic surgery and biological material processing. Its first commercialized product, SMILE surgery equipment is expected to break the monopoly of ZEISS's Visual Max.
As measured by the data center of the Ministry of Culture and Tourism of the People’s Republic of China, 308 million domestic tourism trips were made during the Spring Festival holiday in 2023, an increase of 23.1% year-on-year, recovering to 88.6% of the same period in 2019. The domestic tourism revenue was CNY 375.843 billion, an increase of 30% YoY, recovering to 73.1% of the same period in 2019.
Snack brand Three Squirrels (Chinese: 三只松鼠, SZ:300783) preannounced 2022 Earnings Reports on January 20, 2023. According to the preannouncement, net profit attributable to shareholders is expected to be somewhere between CNY 120 million (USD 17.76 million) and CNY 140 million for 2022, down 65.95% to 70.81% year-on-year. With non-recurring gains and losses excluded, the net profits stood between CNY 40 million and CNY 60 million, down 81.23% to 87.49% year-over-year. Three Squirrels stated that performance in Q4 2022 fell short of the company's own expectations because the production and delivery of its major products were affected by the first wave of COVID-19 infections after the relaxation of relevant restrictions.
Chinese blind box e-commerce platform Liduoduo (Chinese: 礼多多) received USD 57 million in an angel round led by FOXZZ INVESTMENT on January 28. Proceeds are said to be put into strengthening marketing, improving supply chain management, growing sales channels, and expanding overseas markets. Liduoduo is an e-commerce platform where cosmetics, snacks, trendy toys, and other products are sold in blind boxes. It provides online blind box shopping, opening, and reselling services. The company received USD 20 million from FOXZZ INVESTMENT in October 2022. Press release content from EIN Presswire.
Levostar (Chinese: 左旋星生物) has raised the second financing round since its founding in 2022, which was led by Matrix Partner (Chinese: 经纬创投). Proceeds will be used to expand the GMP-level production and upgrade safety testing and evaluation platform for CGT products. Levostar is a developer and producer of cell gene therapy products intended to provide breakthrough technologies and full-coverage solutions for the CGT industry. The company's products include its clinical testing services for cell therapy platforms, viral vector platforms, mRNA vaccines and therapeutic platforms, and GMP-level production processes and product quality control methods for plasmids and mRNAs, enabling the biotechnological industry to accelerate the process of gene cell therapy and mRNA drug research and developm
Statistics from the China Film Administration show that the box office of Chinese films during the 2023 Spring Festival ( Jan 21 to Jan 27) was CNY 6.758 billion, an increase of 11.89% year-on-year, with 99.22% of the box office generated by domestic films. The number of moviegoers was 129 million, an increase of 13.16% year-on-year. The types of film themes during this year's Spring Festival were richer and more diversified in style than in previous years. Chinese domestic films such as "Full River Red"(Chinese:满江红) and "The Wandering Earth II" (Chinese:流浪地球II)have made an effort to expand their content and expression, using their works to attract audiences to the cinema and help the Chinese film market recover rapidly.
Chinese online travel service company Ctrip released the "2023 Spring Festival Travel Summary Report" on January 27. The report shows that, as the first Spring Festival since 2019 where people do not have to spend their New Year locally, China's travel market has delivered the brightest performance since COVID-19. On Ctrip's platform, domestic and international travel orders during the Spring Festival saw a three-year peak, with travel orders increasing four-fold compared to the 2022 Spring Festival. Meanwhile, as the first long holiday after the liberalization of cross-border travel, Chinese tourists went abroad to enjoy the Chinese New Year overseas. Chinese outbound travel orders during the Spring Festival grew by 640% year-on-year, with overseas hotel orders up more than four times.
YingHe Neuro (Chinese: 应和脑科学) announced that it had completed a CNY 100 million Angel round co-led by BioChing Capital (Chinese: 邦勤资本) and LAV (Chinese: 礼来亚洲基金) and followed by Snibe Diagnostic (Chinese: 新产业生物), XiJiao 1896 innovation fund (Chinese: 西交一八九六科创基金), and its existing backer Enlight Medical (Chinese: 应脉医疗). DeepSnow Capital (Chinese: 深雪资本) acted as the financial adviser. YingHe Neuro focuses on the development of a new generation of neuromodulation and brain-computer interface products and technologies based on clinical demands.
According to statistics released by the Department of Commerce of Hainan Province on January 26, during the 2023 Chinese New Year holiday (January 21 to 25), the province's 12 duty-free shops recorded total sales of CNY1.685 billion, an increase of 20.03% over the 2022 Chinese New Year and 325% over the 2019 Chinese New Year. Among them, six duty-free shops in Haikou City recorded total sales of CNY470 million, up 140% from the 2022 Chinese New Year and up 641% from the 2019 Chinese New Year; four duty-free shops in Sanya City recorded total sales of CNY1.158 billion, up 253% from the 2019 Chinese New Year.
Lu Xi He (Chinese: 泸溪河) secured CNY 100s of millions in a Series A round led by Jiangsu Bailian Confitop Venture Capital Management (Chinese: 百联挚高资本) and Cypress Capital (Chinese: 龙柏资本). Proceeds from the round will be put into supply chain management and digitalization. Founded in Nanjing in 2013, Lu Xi He (Chinese: 泸溪河) is a bakery chain making Chinese pastries. It has over 360 directly operated stores nationwide. Jiangsu Bailian Confitop Venture Capital Management stated that it will leverage abundant retail resources to assist Lu Xi He in expanding offline channels and growing into a leading bakery brand.
Dong Fang Zhen Xuan (Chinese: 东方甄选) recently released its earnings for the first half of the fiscal year 2023 (June 1, 2022, to November 30, 2022). Its gross merchandise volume from June to November 2022 reached CNY 4.8 billion (USD 708 million) and its total revenues were CNY 2.08 billion, up 262.7% from CNY 573 million in the same period of FY2022. Net profit from continuing and discontinued operations for the reporting period was CNY 585 million. Dong Fang Zhen Xuan, a live-streaming e-commerce platform selling agricultural products, books, and household goods, was launched in 2021 by Koolearn Technology Holding Ltd (Chinese: 新东方在线, HK01797). The platform became widely popular after its bilingual live-streaming went viral in China.
Suzhou Ovodan Foods Co., Ltd (Chinese: 苏州欧福蛋业股份有限公司, hereinafter referred to as “Ovodan Foods”) was successfully listed on the Beijing Stock Exchange on 18 January 2023 at a price of CNY 2.50 per share, becoming the first foreign-funded listed company on the Beijing Stock Exchange. The company's controlling shareholder is China Egg Products ApS (Denmark) with a total stake of 87.96 percent. Established in January 2004, Ovodan Foods is a Chinese member of the world famous egg products supplier -OVODAN (formerly known as Sanovo Egg Group). According to the firm's prospectus, it aims to get about CNY153.70 million (USD 22.09 million) to upgrade assembly line, expand production and add more liquidity.
Chinese casual food company Yanjin Shop Food Co., Ltd. (Chinese：盐津铺子；hereinafter referred to as "Company") released an earnings preview on January 18 showing that the company expects to achieve a net profit attributable to shareholders of the listed company of CNY 296 million to CNY 304 million in 2022, an increase of 96.36% to 101.67% over the same period of the previous year. in 2022, the company continued to increase its investment in research and development expenses, which amounted to CNY 74.3 million. Yanjin Shop was established in 2005. It is a group company engaged in food research and development, production and sales.On February 8, 2017, the company was listed on the A-share SMEs board of Shenzhen Stock Exchange (Securities Code: 002847).
Genderless apparel brand bosie closed a CNY 100 million Series B2 round of funding on January 17 from individual investors, and the use of the proceeds was not disclosed. Founded in 2018, bosie has completed eight rounds of funding to date, with investors from organizations and companies including Eastern Bell Capital (Chinese: 钟鼎资本), 5Y Capital (Chinese: 五源资本), Genesis Capital (Chinese: 元生资本), Cyanhill Capital (Chinese: 青山资本), GSR Ventures (Chinese: 金沙江创投), Zhen Fund (Chinese: 真格基金), and bilibili (Chinese: 哔哩哔哩). According to its official social media account, bosie is a gender-neutral clothing brand targeting the "Generation Z" consumer group born after 1995. Currently, bosie has 8 directly-managed shops and 24 affiliated shops in China, mainly in first-tier cities.
According to the Shanghai Municipal Commission of Commerce, as the impact of the pandemic in China gradually receded, the 2023 Chinese New Year dinner market gradually entered a recovery phase, showing flourishing scenes of dine-in and pre-made dishes bookings. 1.Dine-in bookings for the 2023 Chinese New Year dinner were launched in November 2022, and in December, the cancellation rate was once as high as 50% due to the social spread of the pandemic. With the recent receding of the epidemic, the rebooking rate has rapidly increased, and the reservation of New Year's Eve dine-in has reached over 80%. 2. Due to the pandemic, pre-made dishes have been known and accepted by more consumers in recent years, and have become a popular choice for New Year's Eve dinner.
Apple Inc. partners Foxconn Technology Group (Chinese:富士康) and Pegatron Corp. (Chinese:和硕)included Southeast Asia in their expansion plans for 2023, in a sign major global contract electronics manufacturers will continue to add production capacity outside China to mitigate geopolitical and economic risks. “We will continue to grow our scale in mainland China, the Americas and Southeast Asia, and these efforts will blossom in 2023,” said Young Liu, chairman of Foxconn's flagship unit Hon Hai Precision Industry Co., at a company event on Sunday. Separately, Foxconn's smaller rival Pegatron will allocate $300 million to $350 million this year to capital expenditure, partly to grow capacity in Southeast Asia and increase automotive component production in Mexico, company executives told rep
BlissBio (Chinese: 百力司康) announced that it had completed a CNY 100 million Series B+ financing round, which was led by In Capital (Chinese: 约印医疗基金) and followed by its existing investors Oriental Fortune Capital (Chinese: 东方富海) and Sherpa Healthcare Partners (Chinese: 夏尔巴资本). Proceeds raised in this round will be used in the advancement of clinical research of BB-1701, BB-1705, BB-1709 programs, pre-clinical research and registration of product pipelines, and the preparation of new drug application. BB-1701 is a new antibody-drug conjugate (ADC) under Phase II clinical trial. Its toxin Eribulin, licensed from Eisai, is an oncology product on the market with clinically proven safety and efficacy profiles.
PowerSite (Chinese: 博思得) announced that it had raised a CNY 100 million Series B financing round, which was led by bioVENTURE (Chinese: 元生创投) and followed by Jiangsu Medpark (Chinese: 江苏医疗器械科技产业园) and its existing investors including SND Venture Capital (Chinese: 苏高新创投), Northern Light Venture Capital (Chinese: 北极光), and QianHui Capital (Chinese: 乾汇资本). Proceeds raised in this round will accelerate the R&D of new technology and product, the expansion of capacity and business, and the improvement of its market position. PowerSite is a medical equipment company offering overall scheme for the core components of high-end X-ray image systems.